
William Gradishar
Articles
-
2 weeks ago |
oncologynewscentral.com | William Gradishar |Robert A. Figlin
Data from the SERENA-6 trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting, have the potential to dramatically change advanced estrogen receptor–positive, HER2-negative breast cancer care, says William J Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine in Chicago. The study showed benefit in switching therapies based on circulating tumor DNA evidence of ESR1 mutation, ahead of disease progression.
-
Mar 6, 2025 |
nature.com | R. C. Coombes |Simon Lord |Zahi Mitri |Carlo Palmieri |William Gradishar |Patrick Ward | +2 more
Correction to: Nature Communications https://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row...
-
Jan 8, 2025 |
jwatch.org | William Gradishar
-
Jan 3, 2025 |
jwatch.org | William Gradishar
William J. Gradishar, MD, reviewing The selective estrogen-receptor degrader imlunestrant improved progression-free survival compared with endocrine therapy. The development of new oral selective estrogen-receptor degraders (SERDs) has increased the treatment options for metastatic ER+/HER2− breast cancer. Imlunestrant is a brain-penetrant SERD shown to have clinical activity in endocrine-refractory tumors, including those that develop ESR1 mutations. It is not yet FDA approved.
-
Nov 22, 2024 |
jwatch.org | William Gradishar
William J. Gradishar, MD, reviewing Combining endocrine therapy with a CDK4/6 inhibitor and a PIK3CA inhibitor improves outcomes in patients with ER+/HER2− metastatic breast cancer and PIK3CA mutations.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →